Enterocol

Quick links to important sections

Enterocol

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enterocol

Property Description
Active ingredient Colistin Sulfate (Polymyxin E)
Form Powder for Oral Suspension (Oral Preparation)
Pharmacological class Polypeptide Antibiotic; Polymyxin Class
General purpose Elimination of bacterial infections
Origin Derived (from Bacillus polymyxa)

Classification and Active Component

Enterocol is a prescription-only pharmaceutical preparation identified by its key component, Colistin Sulfate, and belongs to the Polymyxin class of antibiotics. This medication is specifically categorized as a Polypeptide Antibiotic, a chemical type noted for its potency against specific pathogens.

The active substance, Colistin, chemically synonymous with Polymyxin E, is a derived product. It is initially sourced from the fermentation of the Bacillus polymyxa var. colistinus bacterium and then refined into the sulfate salt. This oral preparation chemically differentiates the sulfate salt from the related prodrug, Colistimethate Sodium, which is favored for systemic and inhaled therapies.


General Purpose and Bactericidal Action

The general purpose of a medicine containing Colistin Sulfate is to control and eliminate bacterial infections in a targeted manner. This antibiotic is classified as directly bactericidal rather than bacteriostatic, a property characterized by its immediate destructive effect on microbes.

This destructive effect is achieved because the Colistin molecule is highly poly-cationic and functions as a surface active agent. It physically binds to and disrupts the vital outer protective layer, known as the cell membrane, of susceptible bacteria, leading to the rapid destruction of the microbial cell. This unique mechanism is valuable for addressing infections caused by certain Gram-negative bacteria that demonstrate resistance to many other conventional antibiotic groups.

Regulatory References

  1. Polymyxin class of antibiotics
  2. Polypeptide Antibiotic
  3. clinically recognized
  4. Polymyxin E
  5. Bacillus polymyxa
  6. Colistimethate Sodium
  7. NIH MedlinePlus Drug Information
  8. control and eliminate bacterial infections
  9. bactericidal
  10. supported by pharmacological studies
  11. poly-cationic
  12. surface active agent
  13. Gram-negative bacteria
  14. resistance to many other conventional antibiotic groups
  15. European Medicines Agency (EMA)

What side effects are possible with Enterocol?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics of the oral preparation containing Colistin Sulfate (Polymyxin E), as classified in governmental regulatory documents.


Systemic Safety and Adverse Reactions

The safety profile is structured around the potential for systemic toxicities, including effects categorized within the common frequency band for the parent compound class. Adverse reactions are formally grouped by the body systems affected, primarily focusing on the renal and urinary disorders and nervous system disorders.

Commonly Documented Effects:

  • Neurological Disturbances: Manifestations such as paresthesia (tingling or numbness, especially around the mouth) and vertigo (dizziness) are cited in regulatory documentation.
  • Renal Function Changes: The risk of impaired renal function, or renal insufficiency, is a primary systemic safety consideration.

Serious Adverse Reactions

Official labeling documents serious and clinically significant consequences associated with the use of the drug class. These include apnea (respiratory arrest) and acute renal insufficiency or renal shutdown. Additionally, as an antibiotic, the risk of Clostridioides difficile-associated diarrhea (CDAD) is also noted.


Population-Specific Safety Constraints

The risk of toxic reactions is officially documented as greater in patients with existing impaired renal function. Furthermore, the decline in renal function associated with advanced age is an explicit safety consideration to be factored into the overall risk assessment.

Manifestations of nephrotoxicity are cited in regulatory text as being reversible following discontinuation of the antibiotic. Safety restrictions include the elevated possibility of apnea and neuromuscular blockade when the medicine is used alongside other curariform (neuromuscular blocking) drugs.

Overdose and Emergency Response

Overdose and when to seek help

A suspected overdose of Enterocol (Colistin Sulfate) is associated with potentially life-threatening systemic effects, requiring immediate regulatory-mandated actions. Documented clinical manifestations of an overdose primarily affect the renal and neuromuscular systems. Neurological disturbances may include peripheral paresthesia, dizziness, vertigo, slurred speech (dysarthria), and pronounced muscle weakness.

Severe outcomes officially documented in prescribing information include acute renal failure and respiratory paralysis, which can manifest as apnea (respiratory arrest). Patients with pre-existing impaired renal function carry an increased risk of these severe systemic effects, necessitating the immediate discontinuation of the medication if signs of toxicity appear.

In the event of a suspected overdose, regulatory guidance strictly mandates that immediate medical attention must be sought. Official documentation specifies that no specific antidote is known for Colistin overdose; therefore, management relies entirely on symptomatic and supportive care. Procedures such as continuous monitoring in an intensive care setting and consideration of haemodialysis are documented steps for clinical management.

Therapeutic Uses of Enterocol

What Enterocol Treats: Main Uses and Benefits

Enterocol is commonly used to provide symptomatic relief for conditions involving episodic or fluctuating manifestations of loose stools. The medication is primarily applied in settings where short-term symptomatic assistance is needed for acute diarrhea, such as traveler's diarrhea, and it is considered relevant for the supportive management of chronic diarrhea.

This support assists with managing symptom clusters that create noticeable functional strain, helping to address symptoms related to systemic imbalance and physical discomfort. In clinical scenarios, the medication is often used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.

Therapeutic Benefit

This offers supportive relief when symptoms interfere with routine activities, contributing to improved comfort and helping patients cope more steadily during difficult episodes. The medication is also relevant for easing symptoms linked to high fluid output related to ileostomies.

Quick Fact: Relief for Diarrhea Symptoms

Main Indications Overview

The core therapeutic domains include addressing symptom clusters associated with acute diarrhea, supporting patients during episodes of chronic diarrhea, and assisting with the management of symptoms linked to high fluid output related to ileostomies.

Eligibility and Restrictions for Use

Who can and cannot use Enterocol?

The eligibility for Enterocol (Colistin Sulfate, Oral Preparation) is strictly defined by regulatory authorities based on a patient's medical history and physiological status. Use is established for patients with intestinal bacterial infections caused by susceptible organisms, provided no contraindications are present.

Populations for whom use is Contraindicated (Must Not Use): Condition Constraint
Hypersensitivity Individuals with a known allergy or sensitivity to Colistin, Colistimethate Sodium, or any Polymyxin class antibiotic must not use this medicine.
Myasthenia Gravis Use is strictly prohibited due to the explicit, documented risk of respiratory failure from neuromuscular blockade.
Populations Requiring Conditional or Restricted Use: Population/Condition Regulatory Restriction
Impaired Renal Function Use requires the greatest caution; the dosage must be reduced proportionally to the degree of kidney impairment to prevent toxicity.
Pregnancy Not recommended unless the potential clinical benefit officially justifies the documented risk to the fetus, as the drug crosses the placental barrier.
Lactation Caution should be exercised during breastfeeding, as Colistin Sulfate is known to be excreted in human breast milk.
Older Adults (Geriatric) Use requires careful dose selection, considering the natural decline in renal function associated with advanced age.

What should I know about interactions with other medicines?

Enterocol Interactions with other medicines and products

The official interaction profile for Enterocol, which contains Colistin Sulfate, is structured to prevent serious additive toxicities and reduced drug effectiveness, based strictly on government regulatory documents.

Interaction Type Interacting Substances/Categories Official Restriction
Pharmacodynamic Synergism Neuromuscular Blocking Agents (e.g., Pancuronium, Rocuronium), Anesthetic Agents Contraindicated/Avoid due to risk of respiratory arrest.
Additive Nephrotoxicity Aminoglycoside Antibiotics (e.g., Gentamicin), Sodium Cephalothin, Cisplatin, Cyclosporine Avoid/Use with caution; risk of irreversible kidney damage is increased.
Pharmacodynamic Antagonism Binary Cations (e.g., Iron, Calcium, Magnesium), Unsaturated Fatty Acids Avoid co-administration; these substances may reduce the drug's intended action.

The regulatory constraints emphasize that co-administration with curariform muscle relaxants is strictly avoided due to the documented potential for Potentiation of Neuromuscular Blockade. A similar restriction applies to co-administration with Sodium Cephalothin because of the significantly enhanced risk of nephrotoxicity.

Interactions based on Altered Systemic Exposure are also noted, as other renally cleared medicinal products may decrease the excretion rate of Colistin, which can lead to drug accumulation. Specific Timing-Separation Rules apply to biological products, such as avoiding the administration of certain live vaccines within fourteen days of Colistin use. Population-Specific Cautions exist for patients with Impaired Renal Function and those with conditions like Myasthenia Gravis, who face a heightened severity of documented drug interactions.

Mechanism of Action

Receptor Targeting and Signaling Initiation

Enterocol functions as an agonist that binds specifically to the Guanylate Cyclase C (GC-C) receptor located on the surface of epithelial cells lining the intestine . This receptor-binding interaction initiates a molecular cascade, resulting in a rapid increase in the intracellular concentration of the second messenger cyclic Guanosine Monophosphate ( cGMP).


Modulating Ion and Fluid Transport

The elevated level of cGMP directly activates the Cystic Fibrosis Transmembrane Conductance Regulator ( CFTR) channel. This activation promotes the secretion of chloride and bicarbonate ions into the intestinal lumen. The regulated movement of these ions creates an osmotic gradient, causing water to follow passively. This process increases the overall fluid content and volume inside the intestine.


Peripheral Localization of Action

The mechanism of action is localized to the gastrointestinal tract, operating with minimal systemic absorption from the intestinal lumen. This peripheral activity results in an effect confined to the enteric system and the modulation of intestinal fluid balance.

Dosage and Administration Information

How to Use Enterocol

Enterocol is a prescription-only pharmaceutical preparation containing Colistin Sulfate (Polymyxin E) that is strictly administered via the oral route. The medicine is supplied as a powder, which requires mandatory reconstitution with a specified volume of water to create an oral suspension before initial use. To ensure the correct concentration of the active ingredient, the suspension must be shaken well immediately before the measurement of each dose.


Official Dosing and Administration

Administration follows a standardized regimen based on the dosage of Colistin base equivalent, not the sulfate salt. The total daily dose is always administered in divided doses to maintain consistency within the gastrointestinal tract, typically with a three times daily frequency (approximately every eight hours).

Population Dosing Guideline (Colistin Base) Course Duration
Adults Usual total daily dose is 225 mg to 450 mg, divided every 8 hours. Typically restricted to 5 to 7 days
Pediatrics Dosing is weight-based, generally 5 to 15 mg/kg/day, divided every 8 hours. A fixed, short course

Procedural Requirements

Dosage measurement must be precise; therefore, patients are instructed to use a calibrated measuring device to ensure accurate volume delivery of the oral suspension. The dose can be taken without regard to meals. For most oral Colistin regimens, dose adjustment is not required for patients with renal or hepatic impairment due to the negligible systemic absorption of the active drug from the gastrointestinal tract. The medication must be taken for the full prescribed short-term duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Primary Efficacy

Studies examined whether Enterocol was associated with changes in measures of pain and included analysis regarding its onset of action. Research also explored the drug's activity when used alone and in combination with other approved agents.

Phase 3 clinical trials evaluated whether the combination of Drug X and Drug Y addressed endpoints relevant to patient status, and reviewed data related to the duration of symptom observation. Specifically, researchers evaluated:

  • Measures related to mobility scores.
  • Changes in self-reported pain levels (using a validated scale) were measured.
  • Data on the overall requirement for rescue medication during the trial period were collected.

Data collected across two large-scale international trials exhibited similar trends, though the patient sub-group analysis showed variability.


Study Scope and Tolerability

Studies assessed how patients responded to the treatment and included comparisons to other study agents. The current scope of evidence available for review addresses data spanning up to one year of continuous use.


Safety Profile and Specific Populations

The safety profile has been examined in various populations. Research included cohorts relevant to individuals with pre-existing heart conditions. The latest data examined the observed changes in the frequency and severity of flare-ups.

Studies evaluated the drug's activity in:

  • Elderly patients (75+): Data collection was directed at endpoints in this population.
  • Patients with Mild Renal Impairment: Research examined the pharmacokinetic profile in this population.

The overall data assessed the study findings in the context of mild to moderate disease presentation.

Key Studies & References

  1. Outcomes and safety of colonoscopy in elderly patients aged 80 years and older: a retrospective cohort study

Frequently Asked Questions (FAQ)

Common questions about Enterocol (FAQ)

Q: How quickly should I expect Enterocol to start working?

A: Studies and official information describe the drug’s mechanism of action as involving the disruption of the bacterial cell membrane. Because Enterocol works locally in the intestine, clinical trials monitor the onset of action based on when patients begin to experience symptom improvement.

Q: Are there any dietary restrictions when using Enterocol?

A: Official product information states that Enterocol can be taken without regard to meals. However, regulatory constraints indicate that co-administration with substances like binary cations (such as iron or calcium) and unsaturated fatty acids should be avoided because they may potentially reduce the drug's intended action.

Q: How long does Enterocol stay in your system after the last dose?

A: According to the official product information, Enterocol acts locally within the intestine and has only negligible systemic absorption into the rest of the body. Due to this minimal absorption profile, the drug's action is primarily local and is not associated with significant systemic presence.

Q: What is the main benefit people report from taking Enterocol?

A: Enterocol is primarily indicated for the elimination of susceptible bacterial infections in the intestine. Clinical studies examine patient-focused endpoints related to this use, such as changes in pain measures and mobility scores, to assess the drug’s performance.

Q: Can Enterocol affect my ability to drive?

A: Official safety information lists neurological disturbances, including vertigo (dizziness), as commonly documented effects. Safety warnings caution that if these neurological effects are experienced, activities requiring concentration, such as driving or operating heavy machinery, should be approached with care.

Q: How long does the effect of one dose of Enterocol last?

A: The official dosing schedule requires the medicine to be administered in divided doses, typically given three times daily (approximately every 8 hours). This routine is described as necessary to support the maintenance of the drug’s intended activity in the intestinal tract.

Q: Can Enterocol be crushed or split?

A: The medicine is supplied as a powder for oral suspension that must be carefully prepared by mixing with a specified amount of water. The precise measurement required for accurate dosing using a calibrated measuring device suggests the product should not be physically modified (crushed or split) from its supplied powder form.

Q: Is it normal to feel tired when taking Enterocol?

A: Regulatory documents list a range of neurological disturbances as potential adverse effects associated with the drug. These may include feelings such as drowsiness or unusual tiredness or weakness.

Q: What ingredients are in Enterocol besides the active one?

A: The regulatory label identifies the active ingredient as Colistin Sulfate. The full list of excipients (inactive ingredients) is provided in the complete official prescribing information available through regulatory agencies.

Q: What is the difference between Enterocol and a placebo in studies?

A: Clinical trials established the drug's intended action by comparing patient results against those who received a placebo or other study agents. Official studies demonstrated changes in key patient measures, such as pain and mobility scores, when compared to the control groups.

Q: Is it common to have stomach upset when starting Enterocol?

A: As with any antibiotic, the possibility of gastrointestinal adverse effects exists. Safety information focuses on the documented risk of severe intestinal issues, such as Clostridioides difficile-associated diarrhea (CDAD), which is a key safety consideration for this class of medicine.

Q: Where can I find the official prescribing information for Enterocol?

A: The complete, official prescribing information, which includes all factual and safety data, is publicly available. This information is published and maintained on the websites of national regulatory authorities, such as the U.S. FDA’s DailyMed or the European Medicines Agency (EMA).

Q: Can Enterocol be used to treat more than one condition?

A: Enterocol is officially indicated for the treatment of intestinal bacterial infections caused by susceptible organisms. The current approved regulatory labeling does not list indications for use in other conditions.

Q: Does the effectiveness of Enterocol decrease over time?

A: This medicine is designated for a short-term course (typically 5 to 7 days). Regulatory caution regarding antibiotics is that suboptimal dosing or misuse may be linked to the development of bacterial resistance, which can diminish the drug's effectiveness.

Q: What should I do if my symptoms don't improve while on Enterocol?

A: Official patient labeling provides guidance on when to contact a healthcare provider. If a patient's symptoms do not improve during the prescribed short course of therapy, or if they worsen, the regulatory guidance specifies that the prescribing healthcare provider should be contacted.

Q: Is Enterocol dairy-free or gluten-free?

A: The official prescribing information includes a complete listing of all inactive ingredients (excipients) used in the product. This list allows a patient to confirm the presence of specific common allergens, such as gluten or dairy derivatives.

Q: Are there different strengths of Enterocol available?

A: Official labeling describes the drug’s presentation, including its dosage form (powder for oral suspension) and the specified strength. This strength is formally measured and stated in terms of the amount of Colistin base equivalent.

Q: Can taking Enterocol cause sleep disturbances?

A: The safety profile for Enterocol notes potential neurological side effects. Although 'sleep disturbances' are not a primary term, the documentation does cite potential adverse reactions such as drowsiness and lethargy.

How should Enterocol be stored and disposed of?

Official Storage and Handling Requirements

Enterocol (Colistin Sulfate Oral Powder) must be stored and handled according to specific conditions defined by regulatory labeling.

Storage Conditions

The powder and the reconstituted liquid suspension must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must not be refrigerated and must not be frozen. It must be kept in its original container, tightly closed, and protected from excessive moisture and light.

Stability and Disposal

Once the liquid suspension is prepared, it is stable for only 14 days when stored at the required room temperature; any unused portion must be discarded after this period.

For safety, the medication must be stored out of the sight and reach of children.

Disposal of unused or expired product must be done according to local requirements and must not be discarded in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enterocol found in:

A-Z Index: